US FDA accepts Glenmark’s IND application for GRC 54276 to proceed with Phase 1/2 clinical study for… EP News Bureau Mar 16, 2023 GRC54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark
